Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Wants To Expand Clinical Trial Access By Diversifying Investigator Community

Executive Summary

The company’s plan to reduce barriers to clinical trial participation for underrepresented groups includes the creation of nearly 300 new scholarships at medical schools of historically black colleges and universities and minority nursing associations.

You may also be interested in...



Decentralized Trials Are Here To Stay; What Challenges Do They Face?

Decentralized trials took a leap in popularity over the past few years, in part thanks to the COVID-19 pandemic. In Vivo's sister publication Medtech Insight spoke to two executives at clinical research technology companies about running decentralized clinical trials to discuss the benefits and limitations of trials run remotely.

Decentralized Trials Are Here To Stay; What Challenges Do They Face?

Decentralized trials took a leap in popularity over the past few years, in part thanks to the COVID-19 pandemic. Medtech Insight spoke to two executives at clinical research technology companies about running decentralized clinical trials to discuss the benefits and limitations of trials run remotely.

How We Can Use the FDA’s 2022 Diversity Guidance to Make Our Clinical Trials More Inclusive

Catherine Gregor is the chief clinical trial officer at Florence Healthcare, a leading provider of clinical trial software that helps researchers collaborate and manage workflows and information. Based on her extensive experience in clinical research administration, Gregor explains how the recent US FDA guidance on diversity and inclusion in clinical trials represents a critical opportunity to make clinical research more inclusive and equitable.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT144695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel